Cellnex and Inwit have recently pivoted towards buying more land. Why? In part because they still see a good opportunity to deploy capital attractively, but we believe this is also driven by a defensive angle against a gradually rising role of land aggregators in Europe
>Outperform rating maintained – target price raised to € 2.8 (vs € 2.7) - Mapfre turned in another broadly solid set of performances in Q1 2024, both operationally and balance sheet-wise (solvency, etc.) and in synch with the new medium-term strategic plan recently unveiled (March 2024) – net income came in at € 216m (+2% vs consensus), with good-quality performances from its two businesses (non-life +63% vs cons thanks to the financial result, life +7% vs cons). The ...
>Opinion Surperformance maintenue – OC porté à 2.8 € (vs 2.7 €) - Mapfre délivre au T1 2024 une performance de nouveau globalement solide à la fois sur l’opérationnel et l’évolution de son bilan (solvabilité…) et en phase avec le nouveau plan stratégique MT récemment dévoilé (mars 2024). Le RN s’établit ainsi à 216 M€ (soit +2% vs cons) avec une performance de bonne facture des 2 activités (Non-vie +63% vs cons grâce notamment au résultat financier, Vie +7% vs css). L...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
>Organic growth and EBITDA both in line with expectations - Cellnex’s Q1 2024 results were in line with our estimates and with the consensus at the operating level: recurring EBITDA of € 778m vs € 777m from the consensus and € 777m for ODDO BHFe; and EBITDAaL of € 535m vs € 536m from the consensus and € 536m for ODDO BHFe. Organic growth remained strong in the tower business, at a +6.6% increase in PoPs in Q1 2024 (+6.4% in FY 2023), which was still slightly above the...
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, CAF, CELLNEX, FERROVIAL, IBERDROLA, ROVI. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 1Q’24 results to be released over the coming days in Spain. Results and macro data drag down stock markets After three straight days of gains, the business results and the macro data in the US led to stock market losses on both sides of the Atlanti...
>Agreement to manufacture pre-filled syringes for a global pharma company - Rovi has announced that its subsidiary ROIS has entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company. Under the terms of the agreement, ROIS will provide a high-speed production line at its San Sebastián de los Reyes facility, with an estimated annual capacity of 100 million units. The agreement includes the technology transfer for ase...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, CAF, CELLNEX, IBERDROLA, FERROVIAL, ROVI. EUROPA: AIRBUS, DEUTSCHE TELEKOM, SAFRAN, VINCI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. Los resultados y la macro lastran las bolsas Tras tres días de ganancias, los r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.